Published: 1 September 2022
Publications
Recent approvals: new active ingredients or new indications
Prescriber Update 43(3): 40
September 2022
For the period 16 April 2022 to 15 July 2022.
Recent approvals of medicines with new active ingredients
| Trade name (active ingredient) | Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Zematane (alitretinoin) | Liquid filled capsule 10 mg 30 mg |
Eczema |
| Zeposia (ozanimod) | Capsule 920 mcg |
Relapsing multiple sclerosis |
| Zeposia (ozanimod) | Combination capsule 230 + 460 mcg |
Relapsing multiple sclerosis |
| Spikevax* (elasomeran) | Injection 0.2 mg/mL |
COVID-19 prevention |
* Provisional approval
Approved medicines with new indications
| Trade Name (active ingredient) | Dose form and strength(s) | New therapeutic area(s) |
|---|---|---|
| Cabometyx (cabozantinib) | Tablet 20 mg 40 mg 60 mg |
Advanced renal cell carcinoma |
| Actemra (tocilizumab) | Concentrate for infusion 20 mg/mL |
COVID-19 treatment |
See the Medsafe website for:
